Stem Cell Clinic

Stem Cell Stock Alert BioRestorative (OTCBB BRTX) Engages Consulting Firm to Advance brtxDISC Program Delivery Device …

Category: Investment, Biotech, Pharma

Stem Cell Stock Alert: BioRestorative (OTCBB: BRTX) Engages Consulting Firm to Advance brtxDISC Program Delivery Device through FDA Clearance Process

JUPITER, Fla. - September 30, 2013 (Investorideas.com Newswire) BioRestorative Therapies Inc. ("BRT" or the "Company") (OTCQB: BRTX), a life sciences company focused on developing stem cell-based therapies for personal medical applications, announced the engagement of the regulatory consultancy firm Phil Triolo and Associates, LC ("PTA") to help advance the Company's brtxDISC therapeutic procedure through the U.S. Food and Drug Administration ("FDA") regulatory process. The brtxDISC program is the Company's non-surgical investigative treatment for bulging and herniated lumbar discs.

Under the engagement, PTA will assist the Company in its efforts to obtain U.S. regulatory approval and to satisfy FDA regulations applicable to the Company's medical device used in the brtxDISC procedure, including the implementation of quality systems procedures. In addition, PTA will assist BRT in its efforts to satisfy FDA regulations relevant to the combination products (biologic plus device) it ultimately plans to commercialize in the U.S. PTA is also available to assist in any international regulatory approval processes the Company may pursue.

"This is an important step in advancing the development of our brtxDISC procedure," said Mark Weinreb, chief executive officer of BioRestorative Therapies. "We have developed a minimally invasive, technologically innovative medical device to precisely deliver a patient's own stem cells directly into the damaged region of the herniated and bulging disc, which is a key component of the success of the procedure."

"There are approximately one million aggressive surgical back and spine procedures in the U.S. each year, including discectomies, disc replacements and spinal fusions. Our goal is to offer an alternative to these procedures by providing a cellular procedure to assist the patient's body in repairing the disc. Pending regulatory approval, we look forward to commencing clinical trials in mid-2014," Mr. Weinreb added.

Phil Triolo and Associates, LC provides services to assure compliance with U.S. regulatory requirements during all stages of the product lifecycle, from feasibility, design and development, to manufacturing, post-production vigilance and audits.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. ("BRT"), http://www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:

The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls brand at http://www.stempearls.com.

Read more:
Stem Cell Stock Alert BioRestorative (OTCBB BRTX) Engages Consulting Firm to Advance brtxDISC Program Delivery Device ...

Physician First Choice Now Offering IV Stem Cell Therapy for Numerous Medical Conditions with US Board Certified Stem …

Orange County, CA (PRWEB) October 21, 2013

The premier stem cell therapy clinic on the West Coast, Physician First Choice, is now offering IV stem cell treatment for numerous medical conditions. This includes stem cell treatment for Alzheimer's disease, Diabetes, Parkinson's, Liver Disease, Cardiac Disease, COPD and much more. The treatments are provided by US Board Certified Stem Cell Doctors and for more information call (888) 988-0515.

Stem cell therapy has become available for numerous medical conditions and can dramatically improve the patient's baseline. Increasing amounts of research are showing the benefits of IV stem cell therapy for conditions such as diabetes and COPD. Prior to stem cell therapy, these conditions could be managed with traditional medications, but the disease itself could not be altered. With stem cell therapy, that possibility exists.

The Board Certified stem cell doctors at Physician First Choice have over 20 combined years of experience working with patients for both stem cell injection treatment and IV therapy. The clinic treats patients at multiple Southern California locations along with an international location in Mexico. Patient treatment is performed by the same US Board Certified doctors before, during and after therapy to ensure continuity of care.

The program in Mexico involves four days worth of treatment at a first rate clinic, and patients stay at a beautiful hotel with transportation included. IV stem cell therapy is performed along with growth factor treatments to enhance the effect of the bone marrow stem cells.

For conditions such as multiple sclerosis, Alzheimer's or Parkinson's, watching a loved one deteriorate can be disheartening even when the best care is received. Physician First Choice has been having excellent results with IV stem cell treatment for diabetes and these conditions, and the program has been growing exponentially as a result.

The 4 Day Stem Cell Therapy IV Program is offered as a package. Transportation to and from San Diego is included along with the Hotel Stay, All Medical Treatment, Breakfast Each Day, and Transportation between the Gorgeous Hotel and the Stem Cell Treatment Facility. Patients must be approved for program inclusion with a full medical record review and evaluation by the Southern California doctors.

To inquire about program inclusion for IV stem cell therapy, call Physician First Choice at (888) 988-0515.

Read this article:
Physician First Choice Now Offering IV Stem Cell Therapy for Numerous Medical Conditions with US Board Certified Stem ...

International Stem Cell and Regenerative Medicine Community Convenes in Banff, Alberta

OTTAWA, ONTARIO and TORONTO, ONTARIO--(Marketwired - Oct 21, 2013) - Stem cell and regenerative medicine experts from around the world will physically and virtually come together in Banff, Alberta, when Canada's premier stem cell research event - the Till & McCulloch Meetings (T&MM) - takes place October 23-25, 2013.

"Canada and Europe chose the same dates to host their most significant regenerative medicine events and we're utilizing technology to bring the two conferences together," explains Drew Lyall, Executive Director of the Stem Cell Network. "While our European colleagues won't get to enjoy the beauty of Alberta, they will benefit from hearing some thrilling science, produced in Canada."

A novel technology discovered in Dr. Peter Zandstra's lab, which has the potential to improve the viability and success of cord blood stem cell transplantation, will be featured during a live broadcast to the World Conference on Regenerative Medicine in Leipzig, Germany, on October 24 at 8:45 a.m. Dr. Zandstra (University of Toronto and CSO with the Centre for Commercialization of Regenerative Medicine) has received the 2013 Till & McCulloch Award for having published the year's most influential peer-reviewed article by a stem cell researcher in Canada.

Other highlights include the following:

October 23 at 12:20 p.m.

The conference will premiere and showcase a series of short, animated videos about basic concepts in stem cell research narrated by world-renowned stem cell scientists. The videos are produced by Ben Paylor, a PhD candidate in experimental medicine at the University of British Columbia, and Mike Long, a post-doctoral fellow at the University of Toronto, who engaged award-winning animator David Murowsky and Emmy-nominated composer James Wallace to create the signature animations and music featured in the videos. The three videos are targeted at youth of high school age or older. More details about the videos and the award can be found here: http://bit.ly/15GBOsw.

October 23 at 2:10 p.m.

An afternoon plenary session will focus on current research in cell therapy. The session will include presentations by Dr. Duncan Stewart (Ottawa Hospital Research Institute) on lessons learned in bringing cell therapies to the clinic. He will focus on his recently launched stem cell clinical trial for the treatment of acute heart attack, as well as offer overviews of Canada's strategy for stem cell research going forward and the emerging regenerative medicine technologies market.

"The regenerative medicine market is poised to experience explosive growth in the near future, based on the increasing number of clinical trials, deals, IPOs [initial public offerings] and partnerships happening globally," says Michael May, CEO of the Centre for Commercialization of Regenerative Medicine (CCRM). "Canada's leadership in the field of regenerative medicine is already well known, and it is with events and collaborations like the Till & McCulloch Meetings that we will continue to build a strong infrastructure for future growth in Canada. The fact that this year's conference has engaged 39 industry sponsors - more than twice the number that participated last time - is an indication of just how far we've progressed in a short time."

The Till & McCulloch Meetings, formerly the Stem Cell Network's Annual Scientific Meeting, was renamed in 2012 to acknowledge its expanded focus to include the broader field of regenerative medicine and the business focus of commercializing stem cell- and biomaterials-based products and therapies. In addition to excellent science originating from Canada, Japan, China, Israel, Europe and the United States, the conference will feature industry networking meetings and international efforts to share resources to accelerate progress in commercializing new discoveries.

See the original post:
International Stem Cell and Regenerative Medicine Community Convenes in Banff, Alberta

No evidence to support stem cell therapy for pediatric optic nerve hypoplasia

PUBLIC RELEASE DATE:

22-Oct-2013

Contact: Eileen Leahy e.leahy@elsevier.com 732-238-3628 Elsevier Health Sciences

San Francisco, CA, October 22, 2013 A study performed at Children's Hospital Los Angeles found no evidence that stem cell therapy improves vision for children with optic nerve hypoplasia (ONH). Their results are reported in the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS).

ONH, an underdevelopment of optic nerves that occurs during fetal development, may appear either as an isolated abnormality or as part of a group of disorders characterized by brain anomalies, developmental delay, and endocrine abnormalities. ONH is a leading cause of blindness in children in North America and Europe and is the only cause of childhood blindness that shows increasing prevalence. No treatments have been shown to improve vision in these children.

With no viable treatment options available to improve vision, ophthalmologists are becoming aware that families with children affected by ONH are travelling to China seeking stem cell therapy, despite lack of approval in the United States and Europe or evidence from controlled trials. The American Association for Pediatric Ophthalmology and Strabismus has also expressed its concern about these procedures. In response to this situation, pediatric neuro-ophthalmologist Mark Borchert, MD, Director of both the Eye Birth Defects and Eye Technology Institutes in The Vision Center at Children's Hospital Los Angeles, realized that a controlled trial of sufficient size was needed to evaluate whether stem cell therapy is effective at improving optic nerve function in children with ONH. He agreed to conduct an independent study when asked by Beike Biotech, a company based in Shenzhen, China, that offers treatment for ONH using donor umbilical cord stem cells injected into the cerebral spinal fluid.

Beike Biotech agreed to identify 10 children with bilateral ONH (ages 7-17 years) who had volunteered to travel to China for stem cell therapy and who agreed to participate in the study; Children's Hospital was to find case matched controls from their clinic. However, only two case-controlled pairs were evaluated because Beike Biotech was only able to recruit two patients. Treatments consisted of six infusions over a 16-day period of umbilical cord-derived mesenchymal stem cells and daily infusions of growth factors. Visual acuity, optic nerve size, and sensitivity to light were to be evaluated one month before stem cell therapy and three and nine months after treatment.

No therapeutic effect was found in the two case-control pairs that were enrolled. "The results of this study show that children greater than 7 years of age with ONH may have spontaneous improvement in vision from one examination to the next. This improvement occurs equally in children regardless of whether or not they received treatment. Other aspects of the eye examination included pupil responses to light and optic nerve size; these did not change following treatment. The results of this research do not support the use of stem cells in the treatment of ONH at this time," says lead author Cassandra Fink, MPH, program administrator at The Vision Center, Children's Hospital Los Angeles.

Confounding the trial was that subjects received additional alternative therapies (acupuncture, functional electrical stimulation, and exercise) while receiving stem cell treatments, which was contrary to the trial protocol. The investigators could not determine the effect of these additional therapies.

"This study underscores the importance of scientifically testing these procedures to validate them and also to ensure their safety. Parents of afflicted children should be aware that the science behind the use of stem cell technology is unclear. This study takes a step toward testing this technology and finds no beneficial effect," says William V. Good, MD, Senior Associate Editor, Journal of AAPOS and Clinical Professor of Ophthalmology and Senior Scientist at the Smith-Kettlewell Eye Research Institute.

See more here:
No evidence to support stem cell therapy for pediatric optic nerve hypoplasia

Life Stem Genetics Has New Stock Symbol and New Financing Commitment

LOS ANGELES--(BUSINESS WIRE)--

Life Stem Genetics Inc. (the Company), an emerging innovator in the advancement of Adult Stem Cell therapy announces that the Company's new stock symbol, LIFS, is now active.

The Company is also pleased to release the general details of its recent financing commitment. This financing is for $1 million (the Private Placement) of 1,000,000 units (each, a Unit) at a price of $1 per Unit. Each Unit will consist of one common share of the Company and one warrant to purchase an additional common share of the Company (each, a Warrant Share) at $1 per Warrant Share for a period of one year. The Company is to close the Private Placement within 45 calendar days of this press release.

Gloria Simov, CEO of Life Stem Genetics, commented, "Our new trading symbol and recent financing are key components to provide future value to our shareholders and to our fulfillment of our long term objectives in the emerging Adult Stem Cell therapy industry."

All shareholders of the Company are encouraged to view the Company's complete filings at the following link:

http://www.sec.gov/cgi-bin/browse-edgar?company=Life+Stem+Genetics HYPERLINK "http://www.sec.gov/cgi-bin/browse-edgar?company=Life+Stem+Genetics&owner=exclude&action=getcompany"& HYPERLINK "http://www.sec.gov/cgi-bin/browse-edgar?company=Life+Stem+Genetics&owner=exclude&action=getcompany"owner=exclude HYPERLINK "http://www.sec.gov/cgi-bin/browse-edgar?company=Life+Stem+Genetics&owner=exclude&action=getcompany"& HYPERLINK "http://www.sec.gov/cgi-bin/browse-edgar?company=Life+Stem+Genetics&owner=exclude&action=getcompany"action=getcompany

About Life Stem Genetics

Life Stem Genetics (LSG) is a progressive health care company that focuses on healing with a patients own Stem Cells. Stem Cells for years have been known to heal a variety of ailments successfully and now it is being offered as an efficient and painless way to treat many different illnesses ranging from orthopedic Injuries, neurological disorders such as Parkinsons, and Alzheimers, Cancer, Plastic Surgery, Age Management, Arthritis, Diabetes, Cardiology, COPD, MS, Urology, and many more. Stem Cell Therapy and LSGs proprietary techniques have experienced some of the best results in the industry, helping to repair or re-program damaged or diseased tissues and organs.

LSGs stem cell specialist has performed thousands of stem cell treatments, including the top names in PGA golf, NFL football, NBA basketball, and Major League Baseball. LSG will offer their proprietary treatments through a series of affiliate doctors, and medical clinics, with 60 affiliated clinics so far.

LSGs mission is to create a solid comprehensive approach to the treatment and maintenance of diseases and to break free from the medical insurance world by tapping into an affordable private- pay sector delivering exceptional healthcare free from the medical insurance maze.

See original here:
Life Stem Genetics Has New Stock Symbol and New Financing Commitment

Molecule Increases Growth of Stem Cells, Research Suggests

Recently published results from the Harvard Stem Cell Institutes first-ever clinical trials have identified a molecule that could increase the success rates of umbilical cord blood transplants in cancer patients.

The trials found that umbilical cord blood cells treated with 16, 16-dimethyl prostaglandin E2, a molecule derived from fatty acids and also called dmPGE2, grew more stem cells than untreated umbilical cord blood.

Stem cell growth is particularly promising in the treatment of cancer, which is marked by rapid proliferation of mutated cells and the death of functional, important tissue. Stem cell transplants usually face stringent blood type matching requirements, which can often hinder a patients ability to find a viable donor.

Umbilical cord transplants improve flexibility and safety, however, since blood does not need to be exactly matched and has had less exposure to viruses. Successful implementation of the dmPGE2 molecule could help the approximately 50 to 60 percent of stem cell transplant patients who do not have siblings with a matching blood type.

Led by Leonard I. Zon, chairman of the Harvard Stem Cell Institute Executive Committee and professor of stem cell and regenerative biology, researchers at the HSCI discovered that dmPGE2 spurred stem cell growth through laboratory experiments on zebrafish and then mice. Zon and his team then approached the Dana-Farber Cancer Institute and Massachusetts General Hospital to conduct clinical trials.

The HSCI has several ongoing projects, but researchers work on the dmPGE2 molecule is one of the special projects in the lab, Zon said, adding that the work is one of the most exciting things he has ever done.

Corey S. Cutler, an associate professor of medicine at Harvard Medical School who spearheaded the clinical trials, echoed Zons enthusiasm about the projects potential. The exciting part [about this project] is that its really home-grown technology that was discovered right down the hall, he said. He added that while it may still be many years before the technology is ubiquitously accessible to patients, the fact that we could potentially change the field entirely; its quite amazing.

The study was published online in the weekly medical journal Blood in late August and received support from biopharmaceutical company Fate Therapeutics. Phase II of the clinical testing is designed to evaluate the treatments efficacy in about 60 patients. According to Zon, results should be expected after 18 months.

The HSCI was established nine years ago to translate stem cell technology advances made in the laboratory into clinical applications.

Continued here:
Molecule Increases Growth of Stem Cells, Research Suggests

Desperate Family Turns To Controversial Stem Cell Treatment To Help Toddler

MIAMI (CBS4) When Vicky Bonilla looks into her 3-year-old son Andrews eyes, she sees his desire to communicate like he used to.

The neurologist and therapists tell me that he is more aware than what he is able to express and at times he gets frustrated because he cannot express what he wants, Vicky told CBS4s Natalia Zea.

When his older siblings play peekaboo with him they see glimmers of who Andrew used to be.

Andrew was born with digestive issues, but functioned like any other toddler.

He would walk, talk, play like a regular little boy did, said Bonilla through tears.

And he was his dad Tito Bonillas sidekick.

He would do everything with me. He knew everybodys names. He knew mommy, pappi, he knew the color of your car. He knew everything. It was just amazing, he was so smart, said Tito.

Everything changed in January of 2012. At 2 years old, Andrew went into an emergency room, one of many visits for his digestive problems. But this time, he went into septic shock. Infection took over his body and he flat lined in front of his mom.

I had him on his side, I had his hand on his chest and I felt his heart stop, that denial of No, this is not happening, this is really not happening, Vicky recalled.

Medical staff revived Andrew, but the lack of oxygen caused brain damage and left him severely impaired.

More here:
Desperate Family Turns To Controversial Stem Cell Treatment To Help Toddler

Stem Cell Therapeutics Strengthens CD47 Franchise With Acquistion of Complementary Antibody Program

TORONTO, ONTARIO--(Marketwired - Oct 17, 2013) - Stem Cell Ther apeutics Corp. (TSX VENTURE:SSS)(SCTPF), a biopharmaceutical immuno-oncology company developing cancer stem cell-related therapeutics, today announced that it has entered into an option agreement to exclusively license worldwide rights to a panel of fully human monoclonal antibodies targeting the SIRPa protein (CD172a). The technology was developed by scientists at the University Health Network, the University of Toronto, through the Toronto Recombinant Antibody Centre (TRAC), and The Hospital for Sick Children (SickKids), in Toronto, Ontario.

SIRPa is the ligand of CD47, a molecule upregulated on many hematological and solid tumors. CD47 delivers a "do not eat" signal that su ppresses macrophage phagocytosis, allowing cancer cells, including cancer stem cells, to escape immune-mediated destruction. Stem Cell Therapeutics (SCT) is currently developing a CD47 antagonist, using a modified version of the native SIRPa protein fused to an immunoglobulin Fc region. This SIRPaFc fusion protein has shown remarkable anti-leukemic activity both in vitro and in human xenograft models, and SCT recently announced that the program has entered the IND-enabling phase of drug development. The company expects to report further updates at the upcoming annual meeting of the American Society of Hematology (December 7-10, 2013).

"Targeting the CD47/SIRPa pathway can eliminate bot h bulk cancer cells and cancer stem cells, and engages both the innate and the adaptive arms of the immune system," commented SCT's Chief Scientific Officer, Dr. Bob Uger. "Antibody blockade of SIRPa is a promising approach to activate the anti-tumor activity of macrophages against both liquid and solid tumors, and has the potential as both a monotherapy and combination therapy with other anti-cancer antibodies."

"The CD47/SIRPa axis is one of the most promising a nd compelling next-generation immunotherapy targets in the fight against cancer," remarked SCT's Chief Executive Officer, Dr. Niclas Stiernholm. "Having recently an nounced the advancement of our SIRPaFc program into formal IND-enabling studies, a program we believe is the best-in-class CD47 antagonist currently in development, reinforcing our industry-leading position in this pathway with a complementary antibody program against the SIRPa protein makes eminent sense."

The execution of the definitive license agreement is subject to final due-diligence and certain conditions being met by SCT over the next nine months. The license agreement will contain customary terms and provisions for assets at this stage of development, including an initial license consideration, milestone payments, royalties on sales and sublicensing terms.

SCT Annual and Special Meeting

The company's Annual and Special Meeting of shareholders will be held today at 3:00 pm in the company's offices at 96 Skyway Avenue, Toronto, Ontario, M9W 4Y9. The meeting will include an audio broadcast. To access, please use the following details:

About Cancer Stem Cells:

The cancer stem cell (CSC) concept postulates that the growth of tumors is driven by a rare population of dedicated cells that have stem cell-like properties, including self- renewal. While the bulk of a tumor consists of rapidly proliferating cells and differentiated cells, neither of which is capable of self-renewal, a small population of CSCs provides for long-term maintenance of the cancer. Although the CSC concept was first postulated in the 1960s, it wasn't until 1994 that proof of their existence was demonstrated, when Dr. John Dick and colleagues in Toronto isolated CSCs (known as leukemic stem cells, or LSCs) from bulk acute myeloid leukemia cells. More recently, CSCs have been identified in many other human malignancies, including solid tumors such as bladder, brain, breast, colon, ovarian and prostate cancers. There is accumulating evidence that CSCs are resistant to conventional chemotherapies and radiation. Thus, CSCs are thought to be responsible for a phenomenon well known to oncologists: most patients will experience an initial response to conventional chemotherapies but will ultimately relapse. To cure cancer CSCs need to be destroyed, but the current armament of therapies is poorly equipped to do so.

About Stem Cell Therapeutics:

Go here to read the rest:
Stem Cell Therapeutics Strengthens CD47 Franchise With Acquistion of Complementary Antibody Program

Church: Don’t use human embryos for stem cell cure

Archbishop Socrates Villegas: Killing an embryo is killing a human being (cbcpforlife.com photo)

DAGUPAN CITY, PhilippinesArchbishop Socrates Villegas said the Catholic Church is not against stem cell treatment but is wary that human embryos taken from aborted fetuses have been used in the controversial therapy.

In his pastoral guidance issued Thursday on queries about the morality of the treatment, Villegas said there was nothing generally objectionable about stem cell therapy.

Stem cell research and therapy that use adult human stem cells and stem cells from umbilical cord blood are acceptable as long as they are proven safe and are approved by regulating bodies, Villegas said.

What the Church fears are incidences when such therapy abets directly or indirectly the practice of abortion, he said. [This] is not only morally objectionable [but also] morally repugnant as the use of human embryo means killing a human being in order to save another human being.

We have always believed that a human embryo or fertilized ovum is a (complete) human being although in its primitive form, he said, adding that this entity is irreplaceable.

Killing an embryo in any of its stage of development is killing a human being. This makes it morally repugnant, the bishop said.

Villegas issued the statement in response to requests by the Union of Catholic Physicians for moral guidance regarding the medical issue of stem cell therapy and the ethical dimensions in the practice of their profession.

The dangers and potentials of stem cell therapy, which has become available in the country, have prompted the Church to provide pastoral guidelines for those procuring, providing or regulating such treatment, he said.

He also cautioned people against stem cell therapy that uses plant cells, animal cells and genetically modified human stem cells.

Here is the original post:
Church: Don’t use human embryos for stem cell cure